Overactive bladder is a symptom syndrome characterized by urinary urgency, often with frequency and nocturia, with or without urge incontinence, due to abnormal bladder storage function.
Zydus Lifesciences resolves US patent litigation with Astellas Pharma over generic Mirabegron for $120 million plus per-unit licensing fees through September 2027, enabling continued US marketing.
The Trump administration launched TrumpRx.gov in February 2026, offering discounted prices on dozens of brand-name prescription drugs through negotiated deals with pharmaceutical companies, though critics warn many listed drugs have cheaper generic alternatives.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07513363 |
The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency |
NOT_YET_RECRUITING | NA |
| NCT07463326 |
The Efficacy of Transcutaneous Tibial Nerve Stimulation in Women With Idiopathic Overactive Bladder |
ENROLLING_BY_INVITATION | NA |
| NCT07452796 |
Turkish USIQ: Validity & Reliability |
NOT_YET_RECRUITING | |
| NCT07432659 |
Add-On ZIDA Sock Therapy for Overactive Bladder |
RECRUITING | NA |
| NCT07429734 |
Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women |
NOT_YET_RECRUITING | PHASE3 |
| NCT07387315 |
A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections |
NOT_YET_RECRUITING | PHASE4 |
| NCT07379372 |
Bladder Overactivity and Post-Botulinum Toxin Telemonitoring |
NOT_YET_RECRUITING | NA |
| NCT07357714 |
Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling Elderly |
NOT_YET_RECRUITING | |
| NCT07353944 |
TTNS vs PTNS in a County Hospital System. |
COMPLETED | NA |
| NCT07337252 |
Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy |
COMPLETED |
